ROCR Value Based Program Act
HB2120, the Radiation Oncology Case Rate Value Based Program Act of 2025, would create a new Medicare payment model for radiation oncology services. The bill directs the Secretary of Health and Human Services to establish a Radiation Oncology Case Rate Value Based Payment Program (ROCR) that pays radiation therapy providers and suppliers a bundled, per-episode amount for covered radiation treatment of specified cancer types. The program is intended to replace the current fragmented fee-for-service approach with more stable payments, while also encouraging quality, access, and cost containment.
The bill sets out detailed rules for how episode-based payments would work, including advance and final payments, annual inflation updates, geographic adjustments, and periodic rebasing of payment rates. It also creates special treatment for incomplete episodes, concurrent treatments, and certain new technologies, and it excludes participating providers from the Medicare Merit-based Incentive Payment System. In addition, the bill would exempt the program’s savings from Medicare budget neutrality adjustments, meaning reductions in spending under the new model would not be used to offset other Medicare payment changes.
A major feature of the bill is a new health equity add-on payment tied to transportation insecurity. Providers would receive an extra payment when a patient is identified as having transportation insecurity, and those funds are intended to support free or discounted transportation to radiation therapy appointments. The bill also creates a statutory exception under the federal anti-kickback/civil monetary penalty framework for certain transportation assistance offered by eligible entities, subject to conditions such as no public marketing, no per-beneficiary payment, and limits on who may receive the benefit.
The bill would also impose accreditation and quality-related requirements on participating radiation oncology providers and suppliers, with incentives for compliance and penalties for noncompliance after an initial period. It directs the Government Accountability Office to report later on the program’s effects, including access in rural and underserved areas and whether additional cancer types or radiation modalities should be added. Overall, the bill would significantly amend Medicare payment law in Titles XVIII and XI of the Social Security Act, affecting hospitals, physician group practices, freestanding radiation centers, Medicare beneficiaries with certain cancers, and entities that provide patient transportation.
The available context shows no committee debate or recorded votes, so there is no documented partisan or stakeholder sentiment in the provided materials. Based on the bill text, the policy intent appears generally supportive of radiation oncology providers and patients, especially around payment stability, access, and transportation assistance. Likely points of contention include the mandatory participation requirement, the savings adjustment and potential payment reductions, the accreditation and reporting burdens, and the exemption from budget neutrality rules, which could affect broader Medicare payment calculations.
HB2120 would add a new Section 1899C to the Social Security Act and amend existing Medicare payment provisions in Sections 1833(t), 1848(q), 1848(c)(2)(B), and 1128A. It would shift Medicare payment for many radiation oncology services from separate fee-for-service billing toward bundled per-episode payments, while also creating new payment adjustments, quality incentives, and a transportation-related add-on. The bill would also create a new statutory safe harbor/exception for certain free or discounted transportation offered to radiation therapy patients, and it would exclude participating radiation oncology providers and suppliers from MIPS. These changes would directly affect Medicare reimbursement rules for hospitals, physician practices, freestanding radiation centers, and beneficiaries receiving radiation therapy for specified cancer types.
No votes or committee transcripts were provided, so there is no recorded legislative sentiment in the available history. The bill’s findings and structure indicate a favorable view of radiation oncology providers and patient access, with emphasis on stabilizing payments, supporting rural access, and reducing transportation barriers. At the same time, the bill includes cost-containment language, accreditation requirements, and a savings adjustment, suggesting an attempt to balance provider support with Medicare spending restraint.
The main likely points of contention are the mandatory nature of participation for many providers, the bill’s savings adjustment and reduced payment provisions, and the exemption from budget neutrality, which could have downstream effects on other Medicare payment rates. Providers may also object to accreditation, EHR, and reporting requirements, while others may support them as quality safeguards. Another possible area of debate is the transportation provision: supporters may view it as an access and equity measure, while critics may question fraud-and-abuse implications, administrative complexity, and whether the new safe harbor could be used as a patient steering tool despite the bill’s restrictions.